7,320 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Luts & Greenleigh Group Inc.

Luts & Greenleigh Group Inc. purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 7,320 shares of the biopharmaceutical company’s stock, valued at approximately $304,000.

A number of other large investors have also bought and sold shares of BMY. Citizens Financial Group Inc. RI lifted its holdings in Bristol-Myers Squibb by 29.7% during the second quarter. Citizens Financial Group Inc. RI now owns 35,203 shares of the biopharmaceutical company’s stock worth $1,462,000 after acquiring an additional 8,070 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its stake in Bristol-Myers Squibb by 3.8% in the second quarter. Mesirow Financial Investment Management Inc. now owns 50,808 shares of the biopharmaceutical company’s stock valued at $2,110,000 after buying an additional 1,882 shares during the period. Quantbot Technologies LP bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $7,721,000. Keene & Associates Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.1% during the 2nd quarter. Keene & Associates Inc. now owns 60,313 shares of the biopharmaceutical company’s stock worth $2,505,000 after acquiring an additional 1,249 shares during the last quarter. Finally, Bcwm LLC bought a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth about $4,720,000. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BMY shares. Barclays lifted their target price on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday, August 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research note on Monday. TD Cowen upped their price target on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft cut their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. Finally, Jefferies Financial Group boosted their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $55.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $50.00 on Tuesday. The firm has a market capitalization of $101.36 billion, a price-to-earnings ratio of -16.13, a PEG ratio of 12.59 and a beta of 0.46. The stock’s 50 day moving average is $46.99 and its 200-day moving average is $46.47. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $59.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. Bristol-Myers Squibb’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.75 EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.80%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.